Based on the Hans Clevers models, Epistem offers three dimensional intestinal organoid models in a variety of species (mouse, rat, dog and human). This well-established model can be used for determining the effect of novel therapeutic agents on normal intestinal tissue to predict the in vivo response, typically off target/off tissue toxicities. Multiple therapeutic agents can be quickly and efficiently screened, which requires only small volumes of agent and is possible where in vivo screening may be unfeasible. Organoids contain the stem cells that regenerate the tissues and recapitulate many of the features of the in vivo structure, including all differentiated cell types. They therefore enable the in vitro study of the tissue response – from general effects on proliferation and cell death through to effects on particular cell types, transport and signalling pathways. Candidates evaluated to date include Wnt regulators, cytokines / growth factors, steroids, lectins and kinase inhibitors.
Intestinal Organoid Model Description
Intestinal organoids are taken from established cultures and plated in multi-well plate formats to allow assessment of test agents. Their effects on organoid viability and production of crypt-like branching structures are routinely assessed via visual scoring, alongside cell proliferation assays.
- Viability and proliferation
- In situ hybridisation (RNAscope)
- Cytokine profiling
- Gene expression (NGS, array, PCR from whole organoids or selected cell types)
In vitro organoid services are provided under a licence agreement with the Hubrecht Organoid Technologies (HUB).